IL6 and COVID-19: Drugs that inhibit IL-6, IL-6R and JAK signaling (activated by IL-6 family members) are FDA-approved for the treatment of rheumatoid arthritis and other inflammatory conditions and are currently being evaluated in patients with COVID-19 (Table 2).